Stallion India Fluorochemicals: Riding a Wave of Growth with Strategic Expansions and Helium Focus

Stallion India Fluorochemicals Limited has unveiled a compelling financial performance for Q3 and the first nine months of FY26, underscoring a period of robust growth and strategic advancements. The investor conference call revealed significant year-on-year improvements, bolstered by aggressive expansion plans and key partnerships in the high-value specialty gases segment.

📉 The Financial Deep Dive

The Numbers:
For the third quarter of FY26 (ending December 31, 2025), Stallion India Fluorochemicals reported total revenue of ₹104.87 crore, marking a healthy 23.2% year-on-year growth. EBITDA stood at ₹13.56 crore, while Profit After Tax (PAT) was ₹11.12 crore. The company's Net Profit Margin for the quarter was approximately 10.61%.

The nine-month period (9M FY26) showcased even more impressive momentum. Revenue surged 41.7% YoY to ₹321.18 crore. EBITDA escalated by 48.6% YoY to ₹43.69 crore, and PAT demonstrated a substantial jump of 72.8% YoY to ₹32.9 crore. Earnings Per Share (EPS) for the nine-month period stood at ₹4.15. [cite: user text, 3, 11, 14]

The Quality:
While Q3 EBITDA saw a slight decline of 5.21% YoY to ₹1,356.20 Lakhs, reflecting margin compression in the quarter, the overall nine-month performance highlights operational efficiency. The company is targeting a significant improvement in PAT margins, aiming to elevate from the current ~10% to 16-24% over the medium term. [cite: user text]

The Grill:
Management addressed queries regarding project execution timelines. Delays in the Mambattu and Khalapur plants were attributed to necessary re-engineering and capacity upgrades to meet evolving market demands and export opportunities. Notably, the CEO, Shazad Rustomji, highlighted his personal contribution of interest-free funds to initiate work on the R-32 plant due to initial funding challenges encountered via the preferential issue route. This suggests a proactive management willing to bridge funding gaps to ensure project commencement, though it also points to potential past funding hurdles. [cite: user text]

🚩 Risks & Outlook

Specific Risks:

• Rights Issue: The company is planning a rights issue to fund its expansion, which could lead to dilution for existing shareholders if not strategically priced. A Board Meeting is scheduled for February 5, 2026, to approve terms and record date for the proposed issue, aiming to raise up to ₹364 crores at ₹99 per share.
• Working Capital: Working capital days have increased significantly from 134 days to 193 days, which warrants close monitoring to ensure efficient inventory and receivables management.
• Promoter Holding: Promoter holding saw a marginal decrease of -3.06% over the last quarter, a trend investors will watch.
• Operational Execution: The success of the ambitious expansion projects and strategic tie-ups hinges on efficient execution and timely commissioning.
• Communication Lapse: A recent report highlighted an apology from the company for inadvertent inconsistencies in Q3 FY26 financial reporting due to an IR communication lapse, underscoring the need for robust internal controls.

The Forward View:
Stallion India Fluorochemicals is poised for significant growth, driven by its strategic focus on backward integration and higher-value products. The commissioning of the 10,000 MTPA R-32 manufacturing facility by August 2026 is a key milestone. The Mambattu facility's expansion, incorporating semiconductor and helium capabilities, is expected to be operational soon.

The strategic technology tie-up with SYS Advanced and the long-term partnership with Sharjah Oxygen for liquid helium sourcing are crucial for building a resilient helium supply chain, targeting critical applications in semiconductors, medical imaging, and aerospace. The helium business is projected to contribute ₹200 crore in revenue within five years. [cite: user text, 16, 18, 20]

Management remains confident in achieving the full-year FY26 revenue guidance of ₹430 crore and a sustained 30-35% CAGR over the next three years. The company aims to maintain a debt-free status. [cite: user text]

Investors should closely monitor the rights issue details, the execution progress of the major expansion projects, and the ramp-up of the high-margin specialty gases business, particularly helium.